IF...and I state if! Phase 2 trials are similar to the Phase 1, then 1 billion would seem to be very undervalued, in the eyes of BP's like Roche.
I'm not saying that it will be by the end of next year, we have already seen over the past 3 years 2 or 3 companies bought for more than 1 billion, with not nearly the potential Tapimmune might have.
The market will pay the multiple, the market is all about speculation of what may be...not what might actually be at this moment in time.
It is by no means out of the realm of possibility, as people have already paid that much, and more.
GLTA
BLU
News 
Market Data 
Discover 
AI
